Preclinical development of AMG 139, a human antibody specifically targeting IL-23.


BACKGROUND AND PURPOSE AMG 139 is a human anti-IL-23 antibody currently in a phase II trial for treating Crohn's disease. To support its clinical development in humans, in vitro assays and in vivo studies were conducted in cynomolgus monkeys to determine the pharmacology, preclinical characteristics and safety of this monoclonal antibody. EXPERIMENTAL… (More)
DOI: 10.1111/bph.12904


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics